12 February 2021
Biointelect has made several new appointments to its Sydney and Melbourne-based teams as it experiences strong growth across all its three main consulting workstreams: R&D strategy and planning, biotech commercialisation and strategic market access, health economics and policy.
Biointelect is delighted to announce that Mark Glover will be joining us in the newly created role of General Manager, Biointelect in early March. Mark joins us with over 30 years of diverse healthcare industry experience including multinational Pharmaceutical / Medical Device companies where he gained increasing levels of responsibility including General Manager/Managing Director, Serono Oceania , Allergan ANZ and iNova ANZ where he was actively involved in the sale of iNova to Private Equity. Mark complements this experience with start-up and consulting roles, including at Metacure and Medidata, a leading provider of clinical trial data capture, management and insights solutions.
Mark is passionate about the healthcare industry and has been an active industry contributor for over 20 years with all major industry associations including time on the Board of Medicines Australia. He holds an Honours degree in Biochemistry (University of Cardiff, Wales); a Certificate in Health Economics (Monash University) and a Postgraduate Diploma in Marketing Management (Macquarie University).
Other recent hires include Crissa Kyriazis, who builds on Biointelect’s strategic project management capability and joins as Commercial Project Management Lead. Crissa comes to Biointelect with over 20 years industry experience working in leadership roles in complex multinational and privately-owned healthcare organisations. Her past experience includes commercial lead roles with primary care, critical care, oncology and vaccine portfolios in which she has a strong track record working with stakeholders to deliver results.
Also joining Biointelect as a Project Management Consultant is Lena Miloradovic. Lena is a strategic project management professional PMP® (PMI certified) who has held a variety of project management, technical and operational roles in biotech companies, including a long career at Seqirus as Head of Project Management as well as at CSL in Corporate Portfolio and Governance roles.
Dr. Jack Lambshead is joining us as a Senior Associate and broadens our expertise in regenerative medicine. After completing his PhD in Stem Cell Biology and Materials Science with ARMI, CSIRO and Monash, Jack moved to the UK where he provided medical writing support to global pharmaceutical companies by developing scientific and medical evidence-based non-promotional materials for rare disease therapies. Since returning to Australia, Jack has been working in clinical research ethics at St Vincent’s Hospital Melbourne, and in Commercialisation and Development at CCRM Australia.
These recent appointments build on Biointelect’s broad and executive-level life sciences expertise, enhancing our capabilities across the whole ‘ecosystem’ of life sciences development and commercialisation in Australia. In particular, expanding Biointelect’s capability in new product planning and enabling expansion of our workstreams related to clinical trials and representing off-shore biotechs seeking to leverage R&D tax concessions in Australia.
Biointelect is a strategic planning firm for the biopharmaceutical and medical device sector including commercial, government and not-for-profit organisations. Our clients include early-stage biotech and medtech companies, pharmaceutical companies, universities, research institutes, government and not-for-profit organisations.
Biointelect helps clients to develop and drive strategy, identify and evaluate new business opportunities and engage the right partners. We advise clients on the spectrum of therapeutic development from start up through to post launch, with an Australian and a Global perspective. We strive to be leaders in life sciences commercialisation, with expertise across the ecosystem and engagement in national policy.